Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Colorcon
Medtronic
Harvard Business School
Johnson and Johnson

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,473,420

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,473,420
Title:Systems and methods for treating patients with processed lipoaspirate cells
Abstract: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
Inventor(s): Fraser; John K (Los Angeles, CA), Hedrick; Marc H. (Encino, CA)
Assignee: Cytori Therapeutics, Inc. (San Diego, CA)
Application Number:10/614,431
Patent Claims:1. A method of processing a cell population that comprises adipose-derived stem cells comprising: removing adipose tissue that comprises a cell population that comprises adipose-derived stem cells from a patient; introducing the removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells into a self-contained adipose-derived stem cell processing unit configured to maintain a closed pathway, wherein said self-contained adipose derived stem cell processing unit comprises: a tissue collection container that is configured to receive adipose tissue that is removed from a patient, wherein said tissue collection container is defined by a closed system; a first filter that is disposed within said tissue collection container, wherein said first filter is configured to retain a first component of said unprocessed adipose tissue and pass a second component of said unprocessed adipose tissue, such that said first filter separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises lipid, mature adipocytes, and saline; a cell collection container, which is configured to receive said first component comprising a cell population that comprises adipose-derived stem cells from said tissue collection container, wherein said cell collection container is within said closed system; a conduit configured to allow passage of said first component comprising a cell population comprising adipose-derived stem cells from said tissue collection container to said cell collection container while maintaining a closed system; a cell concentrator disposed within said cell collection container, which is configured to facilitate the concentration of said first component comprising a cell population that comprises adipose-derived stem cells so as to obtain a concentrated population of cells that comprises adipose-derived stem cells, wherein said cell concentrator comprises a centrifuge or a spinning membrane filter; and an outlet configured to allow the aseptic removal of said concentrated population of cells that comprise adipose-derived stem cells; separating and concentrating said cell population that comprises adipose-derived stem cells from said removed adipose tissue within said self-contained cell processing unit while maintaining said closed pathway; and contacting said concentrated cell population that comprises adipose-derived stem cells with an additive.

2. The method of claim 1, wherein said adipose tissue that is removed from said patient is lipoaspirate.

3. The method of claim 1, wherein said adipose tissue that is removed from said patient is obtained by excisional lipectomy.

4. The method of claim 1, further comprising a disaggregation step, wherein said cell population comprising adipose-derived stem cells contained in the removed adipose tissue is mechanically or enzymatically disaggregated from said mature adipocytes and connective tissue present in the adipose tissue that was removed from said patient prior to separation.

5. The method of claim 1, wherein said cell concentrator comprises a spinning membrane filter.

6. The method of claim 1, wherein said cell concentrator comprises an antibody.

7. The method of claim 6, wherein said antibody is selected from the group consisting of AP2, CD3, CD19, and CD11b.

8. The method of claim 1, wherein said cell concentrator comprises a centrifuge.

9. The method of claim 4, wherein said disaggregation step comprises an enzymatic digestion.

10. The method of claim 9, wherein said enzymatic digestion comprises a collagenase.

11. The method of claim 9, wherein said enzymatic digestion comprises a neutral protease.

12. The method of claim 9, wherein said enzymatic digestion comprises trypsin.

13. The method of claim 1, wherein said adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells are at least 0.1% of the cellular component.

14. The method of claim 1, wherein said adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells are between about 2% and about 12% of the cellular component.

15. The method of claim 1, wherein said concentrated cell population that comprises adipose-derived stem cells has a concentration of about 2.times.10.sup.7 cells/100 ml adipose tissue.

16. The method of claim 1, wherein said concentrated cell population that comprises adipose-derived stem cells comprises endothelial precursor cells.

17. The method of claim 1, wherein said additive is a tissue or tissue fragment.

18. The method of claim 1, wherein said additive is demineralized bone.

19. The method of claim 1, wherein said additive is a compound of the thiaglitazone family.

20. The method of claim 1, wherein said additive is insulin.

21. The method of claim 1, wherein said additive is an exogenous DNA.

22. The method of claim 1, wherein said additive is a biological or artificial scaffold.

23. The method of claim 22, wherein said biological or artificial scaffold is a resorbable plastic sheath.

24. The method of claim 1, wherein said additive is an immunosuppressive agent.

25. The method of claim 24, wherein said immunosuppressive agent is selected from the group consisting of cyclosporine, myophenylate mofetil, rapamycin, and antithymocyte globulin.

26. The method of claim 1, wherein said additive is a cell differentiation agent.

27. The method of claim 26, wherein said cell differentiation agent is a cytokine.

28. The method of claim 26, wherein said cell differentiation agent is a growth factor.

29. The method of claim 1, wherein said additive is an antimicrobial agent.

30. method of claim 1, wherein said additive is unprocessed adipose tissue.

31. The method of claim 1, wherein said cell collection container of said self-contained adipose-derived stem cell processing unit comprises a port configured to receive said additive while maintaining a closed, sterile pathway.

32. The method of claim 1, wherein said tissue collection container of said self-contained adipose-derived stem cell processing unit comprises a port configured to receive said additive while maintaining a closed, sterile pathway.

Details for Patent 7,473,420

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial Cytori Therapeutics, Inc. (San Diego, CA) 2021-12-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,473,420

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Baxter
Harvard Business School
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.